In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biosite Diagnostics' Triage cardiac panal:

This article was originally published in Clinica

Executive Summary

Biosite Diagnostics has received the final three 510(k) approvals that will allow it to launch its Triage cardiac panel. The FDA has cleared both the quality and calibration verification controls, and the Triage meter which is used in conjunction with the system. The cardiac panel is used to measure three cardiac markers - creatinine kinase (CK-MB), myoglobin and troponin I - in whole blood samples. Rising levels of these markers have been shown to be indicative of a heart attack.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT080534

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel